The Data Monitoring Committee terminated the study on the basis of futility (insufficient clinical response).

The purpose of this study is to determine the effectiveness of adjunctive treatment of pregabalin with [S,S]-Reboxetine against pregabalin monotherapy in patients with PHN

Inclusion Criteria:

• Patients must have pain present for more than 3 months after the healing of shingles skin rash
• Patients at screening must have a score >/=40 mm on the pain visual analogue scale

Exclusion Criteria:

• Patients with significant renal and hepatic impairment
• Patients with other severe pain, that may impair the self-assessment of the pain due to shingles
• Patients with clinically abnormal electrocardiogram